KR960033471A - 나노현탁액용 제약 담체 - Google Patents

나노현탁액용 제약 담체 Download PDF

Info

Publication number
KR960033471A
KR960033471A KR1019960007541A KR19960007541A KR960033471A KR 960033471 A KR960033471 A KR 960033471A KR 1019960007541 A KR1019960007541 A KR 1019960007541A KR 19960007541 A KR19960007541 A KR 19960007541A KR 960033471 A KR960033471 A KR 960033471A
Authority
KR
South Korea
Prior art keywords
water
alkyl
substituted
carboxy
amino
Prior art date
Application number
KR1019960007541A
Other languages
English (en)
Inventor
게오르크 베더 한스
반 호오게베스트 페터
Original Assignee
베르너 발데크
시바-가이기 아게
게오르크 베더 한스
베지파크트 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 베르너 발데크, 시바-가이기 아게, 게오르크 베더 한스, 베지파크트 아게 filed Critical 베르너 발데크
Publication of KR960033471A publication Critical patent/KR960033471A/ko

Links

Classifications

    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q10/00—Administration; Management
    • G06Q10/08—Logistics, e.g. warehousing, loading or distribution; Inventory or stock management
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06K—GRAPHICAL DATA READING; PRESENTATION OF DATA; RECORD CARRIERS; HANDLING RECORD CARRIERS
    • G06K19/00—Record carriers for use with machines and with at least a part designed to carry digital markings
    • G06K19/06—Record carriers for use with machines and with at least a part designed to carry digital markings characterised by the kind of the digital marking, e.g. shape, nature, code
    • G06K19/067—Record carriers with conductive marks, printed circuits or semiconductor circuit elements, e.g. credit or identity cards also with resonating or responding marks without active components
    • G06K19/07—Record carriers with conductive marks, printed circuits or semiconductor circuit elements, e.g. credit or identity cards also with resonating or responding marks without active components with integrated circuit chips
    • G06K19/0723—Record carriers with conductive marks, printed circuits or semiconductor circuit elements, e.g. credit or identity cards also with resonating or responding marks without active components with integrated circuit chips the record carrier comprising an arrangement for non-contact communication, e.g. wireless communication circuits on transponder cards, non-contact smart cards or RFIDs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Business, Economics & Management (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Theoretical Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Economics (AREA)
  • Dermatology (AREA)
  • Development Economics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Entrepreneurship & Innovation (AREA)
  • Human Resources & Organizations (AREA)
  • Marketing (AREA)
  • Operations Research (AREA)
  • Quality & Reliability (AREA)
  • Strategic Management (AREA)
  • Tourism & Hospitality (AREA)
  • Neurology (AREA)
  • General Business, Economics & Management (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)

Abstract

본 발명은 약간 가용성인 스타우로스포린 유도체, N-벤조일-스타우로스포린을 정맥내 투여하기 위한 제약 조성물의 제조용 제형 기제에 관한 것이다. 이 조성물은 다음의 바람직한 성분으로 이루어진다 : a) 치료제인 스타우로스포린 유도체, b) 폴리옥시에틸렌/폴리옥시프로필렌 블록 공중합체, c) 담체 액체로서의 에탄올 및 물, d) 대두로부터 정제된 레시틴, 및 e) 수가용성 부형제로서의 글리세롤 및 소르비톨.

Description

나노현탁액 제약 담체
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (2)

  1. b) 폴리옥시에틸렌/폴리옥시프로필렌 블록 공중합체, c) 정맥내 투여를 위한 처방 순도를 갖는, 담체 액체로서의 에탄올 및 물, 및 임으로 d) 하기 일반식의 인지질 또는 이러한 화합물의 염, 및(또는) e) 수가용성 부형제로서 글리세롤 및 제약상 허용되는 육탄당을 포함하는 제형 기제.
    상기 식 중, R1은 C10-20아실이고, R2는 수소 또는 C10-20아실이며, R3은 수소, 2-트리메틸아미노-1-에틸, 2-아미노-1-에틸, C1-4알킬, 카르복시에 치환된 C1-5알킬, 히드록시에 의해 치환된 C2-5알킬, 카르복시 및 히드록시에 의해 치환된 C2-5알킬, 카르복시 및 아미노에 의해 치환된 C2-5알킬, 또는 이노시톨기 또는 글리세릴기이다.
  2. 제1항에 있어서, b) 폴리옥시에틸렌/폴리옥시프로필렌 블록 공중합체, c) 담체 액체로서의 에탄올 및 물, d) 대두로부터 정제된 레시틴, 및(또는) e) 수가용성 부형제로서의 글리세롤 및 소르비톨을 포함하는 제약 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019960007541A 1995-03-21 1996-03-20 나노현탁액용 제약 담체 KR960033471A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH80495 1995-03-21
CH804/95 1995-03-21

Publications (1)

Publication Number Publication Date
KR960033471A true KR960033471A (ko) 1996-10-22

Family

ID=4195580

Family Applications (7)

Application Number Title Priority Date Filing Date
KR1019960007540A KR960033470A (ko) 1995-03-21 1996-03-20 정맥내 투여용 나노현탁액
KR1019960007545A KR100194987B1 (ko) 1995-03-21 1996-03-20 입출 감시 시스템
KR1019960007552A KR960034028A (ko) 1995-03-21 1996-03-20 저온 캡슐 및 저온 캡슐이 내장된 용기
KR1019960007484A KR100191221B1 (ko) 1995-03-21 1996-03-20 공중전화망(pstn)에 이용되는 팩스/데이터/음성 다기능 지원 장치 및 그 방법
KR1019960007541A KR960033471A (ko) 1995-03-21 1996-03-20 나노현탁액용 제약 담체
KR1019960007485A KR100191219B1 (ko) 1995-03-21 1996-03-20 실리콘 웨이퍼 제조 공장 폐수의 효율적인 처리 방법
KR1019960007547A KR960035462A (ko) 1995-03-21 1996-03-20 다중 광디스크 구동 장치 및 방법

Family Applications Before (4)

Application Number Title Priority Date Filing Date
KR1019960007540A KR960033470A (ko) 1995-03-21 1996-03-20 정맥내 투여용 나노현탁액
KR1019960007545A KR100194987B1 (ko) 1995-03-21 1996-03-20 입출 감시 시스템
KR1019960007552A KR960034028A (ko) 1995-03-21 1996-03-20 저온 캡슐 및 저온 캡슐이 내장된 용기
KR1019960007484A KR100191221B1 (ko) 1995-03-21 1996-03-20 공중전화망(pstn)에 이용되는 팩스/데이터/음성 다기능 지원 장치 및 그 방법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1019960007485A KR100191219B1 (ko) 1995-03-21 1996-03-20 실리콘 웨이퍼 제조 공장 폐수의 효율적인 처리 방법
KR1019960007547A KR960035462A (ko) 1995-03-21 1996-03-20 다중 광디스크 구동 장치 및 방법

Country Status (12)

Country Link
US (1) US5726164A (ko)
EP (2) EP0733372A3 (ko)
JP (2) JPH08268915A (ko)
KR (7) KR960033470A (ko)
AU (2) AU4809596A (ko)
CA (2) CA2172110A1 (ko)
HU (2) HUP9600701A3 (ko)
IL (2) IL117551A0 (ko)
MX (1) MX9601032A (ko)
NO (2) NO961136L (ko)
NZ (2) NZ286207A (ko)
ZA (2) ZA962249B (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100422763B1 (ko) * 2002-01-17 2004-03-12 주식회사 태평양 경피흡수 촉진 능력이 우수한 식물성 나노입자의 제조 및이를 함유하는 화장료 및 의약용 외용제 조성물

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0733372A3 (de) * 1995-03-21 1998-05-20 Ciba-Geigy Ag Pharmazeutische Formulierungsgrundlage für Nanosuspensionen
US6066602A (en) * 1997-08-07 2000-05-23 Becton Dickinson And Company Waterborne non-silicone lubricant comprising phospholipid and polyether
US6711160B2 (en) * 1998-03-31 2004-03-23 International Business Machines Corporation Packet network telephone interface system for POTS
TWI241915B (en) * 1998-05-11 2005-10-21 Ciba Sc Holding Ag A method of preparing a pharmaceutical end formulation using a nanodispersion
US6200968B1 (en) * 1998-08-06 2001-03-13 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
US7795246B2 (en) * 1998-08-06 2010-09-14 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
KR100660529B1 (ko) * 1999-01-07 2006-12-22 삼성전자주식회사 통신 시스템 및 그의 제어 방법
GB9903547D0 (en) * 1999-02-16 1999-04-07 Novartis Ag Organic compounds
JP3653422B2 (ja) * 1999-08-20 2005-05-25 シャープ株式会社 排水処理方法および排水処理装置
US6979459B1 (en) 2000-04-06 2005-12-27 Perricone Nicholas V Treatment of skin damage using polyenylphosphatidycholine
US6191121B1 (en) * 2000-04-06 2001-02-20 Nicholas V. Perricone Treatment of skin damage using polyenylphosphatidylcholine
US6932963B2 (en) 2000-06-23 2005-08-23 Nicholas V. Perricone Treatment of skin wounds using polyenylphosphatidylcholine and alkanolamines
US6623765B1 (en) * 2000-08-01 2003-09-23 University Of Florida, Research Foundation, Incorporated Microemulsion and micelle systems for solubilizing drugs
KR20020065105A (ko) * 2001-02-05 2002-08-13 동안엔지니어링 주식회사 반도체 세정폐수 중 절삭가공 폐수에서 농축, 회수된실리콘 입자의 재활용 방법
CA2439097C (en) * 2001-03-26 2010-10-12 Novartis Ag Pharmaceutical compositions
CN1582150B (zh) * 2001-10-30 2011-09-07 诺瓦提斯公司 作为flt3受体酪氨酸激酶活性抑制剂的星形孢菌素衍生物
US8435942B2 (en) * 2002-05-31 2013-05-07 Transdermal Biotechnology, Inc. Methods for formulating stabilized insulin compositions
US20040018237A1 (en) * 2002-05-31 2004-01-29 Perricone Nicholas V. Topical drug delivery using phosphatidylcholine
DE10233737A1 (de) * 2002-07-24 2004-02-05 Morphochem Aktiengesellschaft für kombinatorische Chemie Verwendung von Modulatoren des Signaltransduktionswegs über die Proteinkinase Fyn zur Behandlung von Tumorerkrankungen
AU2004262927B2 (en) 2003-08-08 2008-05-22 Novartis Ag Combinations comprising staurosporines
DE102004019413A1 (de) * 2004-04-19 2005-11-24 Phenos Gmbh Hemmung der Proteinkinase C epsilon zur Behandlung von Krankheiten
KR20050102711A (ko) * 2004-04-21 2005-10-27 서울통신기술 주식회사 아이 브이 알 시스템에서의 신호처리장치 및 그 방법
MX2007001155A (es) * 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
US20090155352A1 (en) * 2007-11-20 2009-06-18 Cephalon, Inc. Microemulsion containing indolocarbazole compound and dosage forms containing the same
WO2010049499A1 (en) * 2008-10-30 2010-05-06 Medlite As Formulation for treatment of vaginal dryness
WO2011000811A2 (en) * 2009-06-30 2011-01-06 Novartis Ag Organic compounds
EP2335686A1 (en) * 2009-12-21 2011-06-22 LEK Pharmaceuticals d.d. An aqueous intravenous nanosuspension with reduced adverse effects
US8668937B2 (en) 2011-03-17 2014-03-11 Transdermal Biotechnology, Inc. Topical nitric oxide systems and methods of use thereof
RU2584421C1 (ru) * 2012-05-29 2016-05-20 Бектон Дикинсон Франс Смазочное покрытие и медицинское устройство, включающее данное покрытие
US8871254B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Systems and methods for treatment of acne vulgaris and other conditions with a topical nitric oxide delivery system
US8871256B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Methods and systems for treatment of inflammatory diseases with nitric oxide
US8871262B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Compositions and methods for treatment of osteoporosis and other indications
US8871255B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Treatment of skin and soft tissue infection with nitric oxide
US8871258B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Treatment and prevention of learning and memory disorders
US8871259B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Techniques and systems for treatment of neuropathic pain and other indications
US8871260B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Methods and compositions for muscular and neuromuscular diseases
US8871261B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Cancer treatments and compositions for use thereof
US8871257B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Prevention and treatment of cardiovascular diseases using systems and methods for transdermal nitric oxide delivery
US9314423B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Hair treatment systems and methods using peptides and other compositions
US9314417B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9387159B2 (en) 2013-03-13 2016-07-12 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9339457B2 (en) 2013-03-13 2016-05-17 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9320706B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9295647B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9314422B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9393264B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9295636B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9687520B2 (en) 2013-03-13 2017-06-27 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9393265B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9750787B2 (en) 2013-03-13 2017-09-05 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9724419B2 (en) 2013-03-13 2017-08-08 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US20140271937A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US20140271938A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9314433B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9241899B2 (en) 2013-03-13 2016-01-26 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US9849160B2 (en) 2013-03-13 2017-12-26 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9295637B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Compositions and methods for affecting mood states
US9320758B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US20140271731A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
JP6229865B2 (ja) 2014-08-11 2017-11-15 国立大学法人 東京大学 エピルビシン複合化ブロック共重合体と、抗癌剤とを含むミセル、及び当該ミセルを含む癌又は耐性癌、転移癌の治療に適用可能な医薬組成物
JP6962655B2 (ja) * 2015-07-07 2021-11-05 ライフラフト バイオサイエンシーズ，インコーポレイテッド 低ナトリウムポロキサマー１８８製剤および使用方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4431631A (en) * 1983-01-03 1984-02-14 Colgate-Palmolive Company Aqueous oral solution
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
JP2627158B2 (ja) * 1987-11-20 1997-07-02 ゼリア新薬工業株式会社 脂溶性物質の安定な水溶液
JP2792005B2 (ja) * 1988-08-11 1998-08-27 竹本油脂株式会社 農薬粒剤用崩壊助剤及び該崩壊助剤を含有する農薬粒剤
JP2792006B2 (ja) * 1988-09-22 1998-08-27 竹本油脂株式会社 農薬粒剤用崩壊拡展助剤及び該崩壊拡展助剤を含有する農薬粒剤
EP0733372A3 (de) * 1995-03-21 1998-05-20 Ciba-Geigy Ag Pharmazeutische Formulierungsgrundlage für Nanosuspensionen

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100422763B1 (ko) * 2002-01-17 2004-03-12 주식회사 태평양 경피흡수 촉진 능력이 우수한 식물성 나노입자의 제조 및이를 함유하는 화장료 및 의약용 외용제 조성물

Also Published As

Publication number Publication date
NO961136L (no) 1996-09-23
KR960036463A (ko) 1996-10-28
KR960034092A (ko) 1996-10-22
KR960033470A (ko) 1996-10-22
HUP9600701A3 (en) 2000-06-28
EP0733358A3 (de) 1998-05-20
NO961137L (no) 1996-09-23
IL117551A0 (en) 1996-07-23
KR960035306A (ko) 1996-10-24
AU4809596A (en) 1996-10-03
NZ286207A (en) 1997-04-24
NO961136D0 (no) 1996-03-20
JPH08268893A (ja) 1996-10-15
EP0733372A3 (de) 1998-05-20
US5726164A (en) 1998-03-10
HU9600701D0 (en) 1996-05-28
HUP9600701A2 (en) 1997-02-28
KR100191221B1 (ko) 1999-06-15
EP0733358A2 (de) 1996-09-25
HU9600700D0 (en) 1996-05-28
HUP9600700A2 (en) 1997-02-28
KR100194987B1 (ko) 1999-06-15
ZA962248B (en) 1996-09-23
IL117550A0 (en) 1996-07-23
HUP9600700A3 (en) 2000-06-28
KR960035462A (ko) 1996-10-24
NO961137D0 (no) 1996-03-20
KR960034028A (ko) 1996-10-22
MX9601032A (es) 1998-11-29
AU4809496A (en) 1996-10-03
CA2172110A1 (en) 1996-09-22
JPH08268915A (ja) 1996-10-15
NZ286206A (en) 1997-05-26
ZA962249B (en) 1996-09-23
CA2172111A1 (en) 1996-09-22
KR100191219B1 (ko) 1999-06-15
MX9601033A (es) 1997-09-30
EP0733372A2 (de) 1996-09-25

Similar Documents

Publication Publication Date Title
KR960033471A (ko) 나노현탁액용 제약 담체
KR950031069A (ko) 골손실의 억제 및 혈청 콜레스테롤의 강하 방법
KR960016890A (ko) 스타우로스포린 유도체의 정맥내 투여 용액
ATE172111T1 (de) Arzneizusammensetzungen enthaltend nanokapseln
ATE497384T1 (de) Omega-3 fettsäure enthaltende pharmazeutische zusammensetzungen
EA200100298A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ ПРЕПАРАТЫ С РЕГУЛИРУЕМЫМ ВЫСВОБОЖДЕНИЕМ, СОДЕРЖАЩИЕ ИНГИБИТОР cGMP-ФОСФОДИЭСТЕРАЗЫ-5
ATE270544T1 (de) Halbfeste arzneizubereitung enthaltend isotretinoin
MA26488A1 (fr) Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
NO20000466D0 (no) Farmasoeytisk preparat for sure, lipofile forbindelser i form av en selvemulgerende formulering
KR890016966A (ko) 신규 항바이러스제
KR960700061A (ko) 니코틴 의존상태 치료를 위한 약리학적 제형 (pharmaceutical composition for treating nicotine dependence)
KR890003382A (ko) 항 비루스성 화합물
KR960000247A (ko) 사이클로스포린a 함유 조성물 및 그의 제조방법
HUP9802861A2 (hu) Calendula glikozidok alkalmazása bőrsejtek túlburjánzásával kapcsolatos betegségek, így psoriasis kezelésére alkalmas gyógyászati készítmény előállítására, ezen vegyületek, valamint ezeket tartalmazó gyógyászati készítmények
CA2003289A1 (en) Use of trifluoromethylphenyl-tetrahydropyridines for the preparation of pharmaceutical compositions useful for the treatment of anxiety and anxio-depressive disorders
EP0542930A1 (en) ORAL MEDICINE CONTAINING MELATONINE.
KR960034200A (ko) 항편두통성 인돌릴알킬-피리딘일 및 피리미딘일피페라진의 1,2,5-티아디아졸 유도체
HUP0004058A2 (hu) Készítmények és eljárások biológiai membránok permeabilitásának reverzibilis növelésére
KR940701251A (ko) 콜레스테롤-강하 토코페롤 동족체
PT1517682E (pt) Formulação farmacêutica compreendendo inibidor da renina não-peptídico e tensioactivo
KR940007001A (ko) 새로운 n-신나모일-2-메틸-5-메톡시-3-인돌 아세트산 에스테르, 그 제조방법 및 이를 함유하는 약학적 제제
EP0867181A1 (en) Nasal melatonin composition
KR930019212A (ko) 피소스티그민 유도체와 이의 용도 및 이를 함유한 제약적 조제물
KR970704463A (ko) 스트렙토그라민 유도체, 이의 제조 방법 및 이를 함유하는 약학 조성물(streptogramine derivatives, preparation of same and pharmaceutical compositions containing same)
PT730474E (pt) Formulacoes de estramustina possuindo propriedades farmacologicas melhoradas

Legal Events

Date Code Title Description
N231 Notification of change of applicant
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid